Engineered immune cells take on tough Muscle-Weakening disease
NCT ID NCT06704269
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new treatment called YTB323 for people with generalized myasthenia gravis that hasn't responded to standard therapies. YTB323 is a CAR-T cell therapy, meaning a patient's own immune cells are modified in a lab to better attack the disease. The study will enroll 15 participants to check safety, how long the cells last in the body, and whether they improve muscle weakness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
YTB323 (a CAR-T cell therapy given by infusion)
What this could lead to
If successful, this could point toward a new treatment option for people with hard-to-control myasthenia gravis, potentially reducing symptoms and reliance on other medications.
What could go wrong
This is an early-phase trial with only 15 participants, so results may not apply to everyone. CAR-T therapies can cause serious side effects like cytokine release syndrome and nerve problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Houston Methodist Hospital
RECRUITINGHouston, Texas, 77030, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Novartis Investigative Site
RECRUITINGBordeaux, 33076, France
-
Novartis Investigative Site
RECRUITINGBrest, 29200, France
-
Novartis Investigative Site
RECRUITINGLille, 59037, France
-
Novartis Investigative Site
RECRUITINGChiba, Chiba, 2608677, Japan
-
Novartis Investigative Site
RECRUITINGKyoto, 6068507, Japan
-
Novartis Investigative Site
RECRUITINGSheffield, South Yorkshire, S10 2JF, United Kingdom
-
Novartis Investigative Site
RECRUITINGLondon, SE5 9RS, United Kingdom
-
Thomas Jefferson University
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
Contact
Contact Email: •••••@•••••
-
Univ Cali Irvine ALS Neuromuscular
RECRUITINGOrange, California, 92868, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Wake Forest Univ School of Medicine
RECRUITINGWinston-Salem, North Carolina, 27157-1052, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact